With the midterms looming, vulnerable congressional Democrats are wagering that health care provisions in the just-passed $740 billion reconciliation bill will give them an edge and possibly preserve their razor-thin majorities.

Why it matters: Recent projections show Republicans likely to flip control of the House. But Democrats are trying to reprise their 2018 campaign playbook with messaging around bill language allowing Medicare to negotiate the price of some drugs and extending enhanced Affordable Care Act subsidies for three years.

Driving the news: Rep. Abigail Spanberger (D-Va.), who's locked in one of the most competitive House races in the country, told Axios the difference this time is that Democrats delivered on their promises.

Democratic Senatorial Campaign Committee Chair Gary Peters (D-Mich.) portrays passage of the bill as a victory over the pharmaceutical industry and entrenched Washington interests.

The big picture: Capping prescription drug prices is the most popular provision in the bill, according to a recent Morning Consult poll, which said 76% of voters supported the measure, including 86% of Democrats, 71% of independents and 69% of Republicans.

Yes, but: None of the bill's provisions will take effect before the elections. And the economy and making ends meet will still be foremost on voters' minds, despite falling gas prices and slowing inflation.

Be smart: The bill nonetheless fulfilled decades of Democratic promises that they'd let Medicare directly negotiate the cost of prescription drugs.

Spanberger said while abortion is definitely an issue voters care about, she believes the health policy wins will also shine through.